Considering treatment with nimotuzumab, a significant survival improvement was observed in EGFR positive unresectable HNSCC patients treated with this inhibitor and RT compared to control patients receiving placebo and RT [80]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.